Orogen Therapeutics reported promising preclinical data for its IL-17 program, showing that Orogen compounds demonstrate ~3× greater potency than competitors and deliver ~100× greater exposure in rodent plasma 8 hours after PO administration in the DC cohort.

Orogen Therapeutics is a biotechnology company advancing next-generation small molecule discovery through an AI-enabled DNA-encoded library (DEL) platform. By integrating computational intelligence with precision chemical diversity, we focus on identifying high-quality binders against challenging and high-value biological targets. Our platform is designed to concentrate chemical diversity around biologically relevant binding space, improving hit quality and accelerating the transition from discovery to development. This targeted approach enhances efficiency, reduces attrition risk, and supports the creation of differentiated therapeutic candidates. At Orogen, we are driven by a clear mission: to deliver transformative medicines for patients facing critical unmet medical needs.